A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
for Acral Lentiginous Melanoma
Drug: Ipilimumab
Sites in Coeur d'Alene, Post Falls +301 more locations
Sponsor: SWOG Cancer Research Network
Sex: All·Age: 18+
Code: NCT04511013·Phase 2·Recruiting·Listed Aug 2020